RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation.
Mirschberger, C., Schiller, C.B., Schraml, M., Dimoudis, N., Friess, T., Gerdes, C.A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., Hopfner, K.P., Niederfellner, G., Bossenmaier, B.(2013) Cancer Res 73: 5183-5194
- PubMed: 23780344 
- DOI: 10.1158/0008-5472.CAN-13-0099
- Primary Citation of Related Structures:  
4LEO - PubMed Abstract: 
The EGF receptor (EGFR) HER3 is emerging as an attractive cancer therapeutic target due to its central position in the HER receptor signaling network. HER3 amplifies phosphoinositide 3-kinase (PI3K)-driven tumorigenesis and its upregulation in response to other anti-HER therapies has been implicated in resistance to them ...